A Review of the Effects of Nicotine on Schizophrenia and Antipsychotic Medications
|
|
- Earl Johnson
- 6 years ago
- Views:
Transcription
1 A Review of the Effects of Nicotine on Schizophrenia and Antipsychotic Medications Edward R. Lyon, M.S., Ed.D. Objective: Research on the impact of nicotine on schizophrenia and antipsychotic medications was reviewed to determine ways to improve treatment planning for patients with schizophrenia who smoke and to evaluate smoking cessation programs for this population. Methods: All major research databases were searched. The review focuses on reports published since Results: Smoking improves processing of auditory stimuli (sensory gating) by patients with schizophrenia and may lessen negative symptoms by increasing dopamine in the nucleus accumbens and the prefrontal and frontal cortex. Use of traditional antipsychotics may result in patients smoking more, whereas patients taking atypical antipsychotics may smoke less. Patients who smoke metabolize antipsychotics faster than nonsmoking patients. Smoking cessation programs for outpatients with schizophrenia report a success rate of about 12 percent after six months. No studies of cessation programs for chronically ill inpatients with schizophrenia have been published. Several hospitals have implemented smoking bans with equivocal results. Conclusions: Nicotine affects both schizophrenia and antipsychotic medications. Neurobiological and psychosocial factors reinforce the high use of nicotine by patients with schizophrenia (Psychiatric Services 50: , 1999) Many patients in psychiatric hospitals would smoke two, three, or even four packs of cigarettes a day if an unlimited supply of cigarettes were available. However, most patients do not have an unlimited supply, mainly because of the cost. When patients smoke all of their cigarettes, some may resort to stealing, begging, prostitution, intimidation, and similar behaviors to obtain more. During the past few years, considerable interest and research has been focused on the high use of cigarettes in psychiatric populations. Before the mid-1980s, most studies focused on depression and anxiety. Patients with major depression and anxiety are more likely to smoke than patients without these disorders, and they experience more problems when they attempt to quit smoking (1 6). Several other diagnostic groups have higher rates of nicotine use. They include patients with alcohol abuse and dependence, panic disorder, and personality and adjustment disorders (2). Studies have consistently reported that patients with schizophrenia have the highest rate of nicotine use (2,7,8). Compared with other diagnostic groups, patients with schizophrenia are more likely to be heavy smokers, defined as those who smoke more than one and a half packs a day. Reports from hospitals suggest that chronically ill inpatients Dr. Lyon is director of psychology at the G. Pierce Wood Memorial Hospital, 5847 Southeast Highway 31, Arcadia, Florida ( , edward_lyon@dcf.state.fl.us). with schizophrenia have even higher rates of smoking than other patients with this disorder, and research supports this observation. For example, in a British study of 100 institutionalized patients, Masterson and O Shea (9) found that 92 percent of the men and 82 percent of the women smoked. In 1990 about a quarter of the general U.S. population were smokers 28 percent of men and 22 percent of women (10). The rate of smoking among inpatients with schizophrenia has been found to be between three and four times the rate in the general population. If the average patient with schizophrenia smokes one and a half packs of cigarettes each day, then each year in the United States this patient population smokes more than 10 billion packs of cigarettes, or about $20 billion worth of cigarettes (8). Patients with schizophrenia are also more likely to smoke high-tar cigarettes. One study found that nearly 59 percent of patients with schizophrenia smoked high-tar cigarettes, compared with less than one percent of the general public (11). Patients with schizophrenia also have smoked for longer periods compared with other groups (12,13). Lohr and Flynn (8) point out that these patients prefer cigarettes high in nicotine and frequently smoke them down to the very end. This practice leaves cigarette burns and yellow stains on their fingers, a condition often observed at institutions with chronic psychiatric patients. Although allowing cigarettes to burn to the very end is sometimes attributed to patients forgetfulness or to their psychotic state, another factor may 1346
2 be involved. The highest level of nicotine is found at the very end of the cigarette, and thus this behavior may be reinforcing (9). Until recently the high rate of smoking among patients with schizophrenia was poorly understood. Current research suggests a link between nicotine, schizophrenia, and antipsychotic medication. This link has direct implications for treatment, as well as for the therapeutic milieu in psychiatric hospitals. This paper examines neurobiological and psychosocial factors that contribute to the high rate of smoking among patients with schizophrenia and describes the interaction of nicotine and antipsychotic medications. The effectiveness of smoking cessation programs is reviewed, and recommendations are made for improving treatment of patients with schizophrenia who smoke. Methods The keywords nicotine, schizophrenia, and antipsychotics were used to search all major research databases. All studies located were examined, although not all are reviewed here. For example, several studies related to neuroleptic-induced movement disorders and nicotine were excluded to stay within the word limitations for publication. The review focuses on studies published since Nicotine s stimulation of dopamine could help explain the high use of nicotine by patients with schizophrenia as a form of self-medication to reduce negative symptoms. Results Neurobiology of nicotine and schizophrenia Although several factors are involved in the high rate of smoking among patients with schizophrenia, the area of neurobiology is the most interesting. Neurobiological factors provide the strongest explanation for the link between smoking and schizophrenia because a direct neurochemical interaction can be demonstrated. Nicotine is involved with several neurotransmitters, including glutamate, acetylcholine, serotonin, and norepinephrine, but its effects on dopamine are likely the most relevant in understanding the high use of nicotine by patients with schizophrenia (14,15). Research has shown that nicotine increases mesolimbicocorticol dopaminergic activity in the nucleus accumbens and the prefrontal cortex (16,17). This stimulation of dopamine could help explain the high use of nicotine as a form of selfmedication to reduce negative symptoms (18). Hypofrontality, a reduction in neuronal activity in the frontal and prefrontal section of the brain, is believed responsible for the negative symptoms of schizophrenia (19 21). These symptoms include social withdrawal, apathy, anhedonia, and lack of motivation. Dopamine release in the nucleus accumbens and the prefrontal areas is associated with several pleasurable and reinforcing activities, such as eating and sex, as well as the use of drugs such as cocaine and amphetamines (22). By increasing the release of dopamine, nicotine is believed to produce similar results for patients with schizophrenia. Research reports by Svensson and associates (20) and Grenhoff and colleagues (23) further suggest that this dopamine increase may partially and temporarily reverse symptoms of hypofrontality. Although traditional antipsychotics appear to have a greater impact on positive symptoms than on negative symptoms (8), the newer agents have been shown to reduce negative symptoms (24 26). At least two of the newer antipsychotics have been shown to reduce nicotine use (27,28). These newer drugs are believed to be better than nicotine in reversing hypofrontality (23,25). Thus the atypicals may benefit patients by reducing both nicotine use and negative symptoms. Psychosocial aspects of nicotine and schizophrenia Besides the neurobiological link between nicotine and schizophrenia, psychosocial factors are involved (29). People in the general population report that nicotine use induces relaxation and pleasurable feelings and reduces anxiety, anger, and depression. These effects may have greater importance among patients with a major mental illness because their sources of pleasure and satisfaction are likely diminished. Glynn and Sussman (30) found that most patients with schizophrenia felt more relaxed and less anxious after smoking. Reduction of the negative symptoms of schizophrenia, such as social and emotional withdrawal, through either psychosocial or neurochemical actions, might increase patients interaction with others. Increased social contact may reduce feelings of isolation and thus reinforce nicotine use. The depressive symptoms that are often experienced by patients with schizophrenia also influence the rate of smoking. Studies have shown that depression is associated with increased smoking, more difficulty withdrawing from nicotine, and a greater relapse rate after quitting (31,32). Interaction of nicotine and antipsychotics No evidence links metabolism of medications directly to nicotine. However, polycyclic hydrocarbons in cigarette smoke stimulate the hepatic microsomal system, inducing liver enzymes to increase the metabolism of psychotropic medications (33). Nemeroff and colleagues (34) suggest that the induction of the cytochrome P450 1A2 isoform may explain the increased metabolism. The cytochrome P450 isoenzymes are involved in the oxidative metabolism of 1347
3 several different types of drugs including the majority of antidepressants and antipsychotics. Several studies have reported that smokers require higher levels of antipsychotics than nonsmokers (7,31, 35). Smoking can lower the blood levels of some antipsychotics by as much as 50 percent, requiring a corresponding increase in dosage to achieve therapeutic blood levels. For example, Ziedonis and associates (29) found that the average antipsychotic dosage for smokers in their sample was 590 mg in chlorpromazine equivalents compared with 375 mg for nonsmokers. Other studies have investigated the connection between specific antipsychotics and the rate of smoking among patients with schizophrenia. McEvoy and colleagues (27) found that patients who started haloperidol treatment smoked more, as measured by their expired-air carbon monoxide and plasma nicotine and cotinine levels, than they did at baseline when they were free of antipsychotic medications. The same researchers studied smoking rates among patients switched from haloperidol to clozapine (36). Patients switched to clozapine at therapeutically effective dosages decreased their smoking, while those whose dosages were below therapeutic ranges showed no change in smoking behavior. George and associates (28) found a similar reduction in smoking when patients were placed on clozapine. Albanese and coworkers (37) reported that patients with schizophrenia who were treated with clozapine showed a reduction in alcohol, cocaine, and heroin abuse. This finding is interesting because several of the atypicals clozapine, risperidone, and olanzapine may increase cortical dopamine release in a manner similar to that of nicotine (25,26). Besides clozapine, amperozide, another atypical antipsychotic, also has been reported to reduce negative symptoms of schizophrenia (19,23,24). This finding strengthens the position that the newer antipsychotics may reduce hypofrontality and thus reduce nicotine dependence among patients with schizophrenia. Effects of smoking on auditory physiology Among persons who do not have schizophrenia, the auditory evoked response to the second of two paired auditory stimuli is significantly lower than the response to the first. Patients with schizophrenia have a deficit in this sensory gating function so that their response to the second stimulus is significantly greater than normal. This defect is one of several auditory sensory gating deficits in schizophrenia. Patients impaired ability to filter out background noise in the environment would interfere with attention and with processing sensory stimuli. Patients who were switched to clozapine at therapeutically effective dosages decreased their smoking, while those whose dosages were below therapeutic ranges showed no change in smoking behavior. Adler and associates (38,39) found that subjects with schizophrenia had a marked improvement in auditory gating immediately after smoking, whereas subjects without schizophrenia showed a slight impairment. This finding suggests that nicotine can temporarily normalize the impairment of auditory gating in subjects with schizophrenia. Smoking cessation programs and schizophrenia Patients with schizophrenia not only smoke at high rates but are less likely to stop smoking than persons in the general population (31). One reason may be that patients with this disorder have less motivation to stop smoking (40). More research is needed to compare patients with schizophrenia with other patient groups to determine whether they have less motivation to quit and whether a larger proportion of patients with schizophrenia are unable to stop smoking. Research on smoking cessation programs for patients with schizophrenia is limited. Ziedonis and George (33) conducted a ten-week smoking cessation program for 24 volunteer outpatients with schizophrenia. Patients continued to receive their usual psychiatric treatment. The average patient had smoked for 27 years and at the time of the study smoked about one and a half packs a day. At the end of six months, three patients remained smoke free with nicotine replacement. Traditional smoking cessation treatment may not work for patients with schizophrenia because of their illness. Addington (41) described an eight-week smoking cessation program modified for patients with schizophrenia. To test this approach, 50 patients with schizophrenia participated in one of five smoking cessation groups. Forty-two percent were smoke free for four weeks, 16 percent stopped smoking for three months, and 12 percent were smoke free at six months. Some research indicates that patients with schizophrenia may experience more problems when they attempt to quit smoking. Ziedonis and George (33) found that 71 percent of their sample of patients with schizophrenia reported substantial withdrawal symptoms, which resulted in a smoking relapse. These symptoms included craving, anxiety, concentration problems, irritability, increased appetite, and restlessness. No studies have examined smoking cessation programs for chronic inpatients with schizophrenia. Because of the severity of psychosis in this patient group, it would be difficult to develop and promote such treatment approaches. These patients have 1348
4 marked affective, cognitive, and social disturbances that would make the educational approaches of traditional smoking cessation programs questionable. Clearly, the motivational and cognitive skills necessary to comprehend the need to reduce or eliminate the use of nicotine are compromised among chronic inpatients. Several psychiatric hospitals have attempted a smoking ban, but the results are inconclusive. Velasco and associates (42) reported the effects of a ban on smoking on a 25-bed psychiatric inpatient unit. Immediately after the smoking ban and for two years, they found no increase in calls for security assistance, physical assaults, restraints, or seclusion. Verbal assaults and as-needed medications for anxiety increased immediately after the ban but were not a problem two years later. Haller and colleagues (43) also found little impact on ward milieu after a complete smoking ban was initiated on a locked ward where the median length of stay was two weeks. Although staff anticipated problems before the ban, the majority voted to keep the ban after it was implemented. Patients views were negative both before and after the ban. Greeman and McClellan s study (44) found many problems with a smoking ban at a Veterans Affairs medical center. They reported that 20 to 25 percent of patients experienced significant problems, some of which caused major disruption to their treatment. The authors speculated that problems associated with smoke-free inpatient settings were underreported in the literature. Conclusions and recommendations Nicotine and the polycyclic hydrocarbons in cigarettes have significant implications for patients with schizophrenia who take antipsychotic medications. Research studies cited here suggest that these chemicals may increase dopamine in the nucleus accumbens and the prefrontal cortex. Research further indicates that an increase in dopamine in these areas of the brain has an impact on hypofrontality, a condition believed to be related to the negative symptoms of schizophrenia. The use of nicotine also temporarily improves sensory gating among patients with schizophrenia, which may increase patients ability to interact with their environment. The interaction between nicotine and antipsychotic medications should be considered in clinical decisions. Among patients who smoke, typical antipsychotics are likely to increase smoking, whereas the atypical medications may decrease this behavior. Heavy smoking may decrease the blood levels of antipsychotic medications by as much as 50 percent. Smoking cessation programs for outpatients with schizophrenia have resulted in small reductions in smoking. No reports of smoking cessation programs for chronic inpatients have been published, perhaps reflecting the difficulty of designing such programs for severely ill patients. Several hospitals have experimented with a smoking ban for staff and patients. The results are inconclusive. Some hospitals report few problems, but one research team speculated that problems related to smoking restrictions are underreported. More research on smoking bans is needed. The following recommendations are based on the studies reviewed here. Clinicians conducting psychiatric evaluations of patients with schizophrenia should determine whether and how much patients smoke. Smoking alters the metabolism of psychotropic drugs, a factor that clinicians should consider when prescribing these medications. Patients with schizophrenia who are dependent on nicotine should not be denied smoking opportunities without being provided alternatives. To reduce the distress of patients who cannot monitor their use of cigarettes and thus use up their supply, treatment teams should consider monitoring the use of cigarettes by such patients. Patients who cannot obtain their own supply of cigarettes should be provided the means to acquire them so that they will not resort to prostitution, trafficking, assault, and similar disruptive behaviors. Although atypical antipsychotics may reduce smoking among patients with schizophrenia, other interventions, such as specialized smoking cessation programs, should be developed, especially for chronic inpatients. References 1. Glassman H: Cigarette smoking: implications for psychiatric illness. American Journal of Psychiatry 150: , Hughes JR, Hatsukami DK, Mitchell JE, et al: Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry 143: , Breslau N, Kilbey MM, Andreski P: Nicotine dependence and major depression: new evidence from a prospective investigation. Archives of General Psychiatry 50:31 35, Paulson GW: Addiction to nicotine is due to high intrinsic levels of dopamine. Medical Hypothesis 38: , Anda RF, Williamson DR, Escobedo LG, et al: Depression and the dynamics of smoking: a national perspective. JAMA 264: , Kendler KS, Neale MC, MacLean CL, et al: Smoking and major depression: a causal analysis. Archives of General Psychiatry 50:36 43, Goff DC, Henderson DC, Amico E: Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. American Journal of Psychiatry 149: , Lohr JB, Flynn K: Smoking and schizophrenia. Schizophrenic Research 8:93 102, Masterson E, O Shea B: Smoking and malignancy in schizophrenia. British Journal of Psychiatry 145: , Dalack GW, Glassman AH: A clinical approach to help psychiatric patients with smoking cessation. Psychiatric Quarterly 63:27 39, O Farrell TJ, Connors GJ, Upper D: Addictive behaviors among hospitalized schizophrenic patients. Addictive Behaviors 8: , MacKenzie TD, Bartecchi CE, Schrier RW: The human costs of tobacco use, part 2. New England Journal of Medicine 330: , Calabresi M, Casu G, Dalle Luche R: The prevalence of smoking in psychiatric patients: the effect of institutionalization [in Italian]. Minerva Psichiatrica 32:89 92, Wonnacott S, Draso A, Sanderson E, et al: Presynaptic nicotinic receptors and the modulation of transmitter release, in The Biology of Nicotine Dependence. Edited by Bock G. New York, Wiley, Vidal C: Nicotine potentiation of glutamatergic synapses in the prefrontal cortex: 1349
5 new insights into the analysis of the role of nicotinic receptors in cognitive functions. Drug Development Research 31: , Corrigall WA: Understanding brain mechanisms in nicotine reinforcement. British Journal of Addictions 86: , Lapin EP, Maker HS, Sershen H, et al: Action of nicotine on accumbens dopamine and attenuation with repeated administration. European Journal of Pharmacology 160:53 59, Dalack GW, Healy DJ, Meador-Woodruff JH: Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. American Journal of Psychiatry 155: , Weinberger DR, Berman KF, Illowsky BP: Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: III. a new cohort and evidence for a monoaminergic mechanism. Archives of General Psychiatry 45: , Svensson TH, Grenhoff J, Enberg G: Effect of nicotine on dynamic function of brain catecholamine neurons, in The Biology of Nicotine Dependence. Edited by Bock G. New York, Wiley, Paulman RG, Devous, MD, Gregory RR, et al: Hypofrontality and cognitive impairment in schizophrenia: dynamic singlephoton tomography and neuropsychological assessment of schizophrenia brain function. Biological Psychiatry 27: , Pfaus JG, Damsma G, Nomikos GG, et al: Sexual behavior enhances central dopamine transmission in the male rat. Brain Research 530: , Grenhoff TJ, Tung CS, Ugedo L, et al: Effects of amperozide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo. Pharmacology and Toxicology 66:29 33, Axelsson R, Nilsson A: Clinical effects and pharmacokinetic properties of amperozide. Psychopharmacology 104: , Moghaddam B, Bunney BS: Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. Journal of Neurochemistry 54: , Chouinard G, Jones B, Remington G, et al: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology 13:25 40, McEvoy J, Freudenreich O, McGee M, et al: Clozapine decreases smoking in patients with chronic schizophrenia. Biological Psychiatry 37: , George TP, Sernyak MJ, Ziedonis DM, et al: Effects of clozapine on smoking in schizophrenia outpatients. Journal of Clinical Psychiatry 56: , Ziedonis DM, Kosten TR, Glazer WM, et 1350 Reviewers Needed al: Nicotine dependence and schizophrenia. Hospital and Community Psychiatry 45: , Glynn SH, Sussman S: Why patients smoke (ltr). Hospital and Community Psychiatry 41:1027, Hughes JR: Possible effects of smoke-free inpatient units on psychiatric diagnosis and treatment. Journal of Clinical Psychiatry 54: , Breslau N, Kilbey MM, Andreski P: Nicotine dependence, major depression, and anxiety in young adults. Archives of General Psychiatry 48: , Ziedonis DM, George TP: Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophrenia Bulletin 23: , Nemeroff CB, DeVane CL, Pollock BG: Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry 153: , Salokanga RK, Saarijarvi S, Taiminen T, et al: Effect of smoking on neuroleptics in schizophrenia. Schizophrenia Research 23:55 60, McEvoy J, Freudenreich O, Levin E, et at: Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology 119: , Albanese MJ, Khaantzian EJ, Murphy SL, et al: Decreased substance use in chronically psychotic patients treated with clozapine. American Journal of Psychiatry 151: , Adler LE, Hoffer L, Wiser A, et al: Normalization of auditory physiology by cigarette smoking in schizophrenic patients. American Journal of Psychiatry 150: , Adler LE, Olincy W, Waldo M, et al: Schizophrenia, sensory gating, and nicotinic receptors. Schizophrenia Bulletin 24: , Hall RG, Suhamel M, McClanahan MG, et al: Level of functioning, severity of illness, and smoking status among chronic psychiatric patients. Journal of Nervous and Mental Disease 183: , Addington J: Group treatment for smoking cessation among persons with schizophrenia. Psychiatric Services 49: , Velasco J, Eells TD, Anderson R, et al: A two-year follow-up on the effects of a smoking ban in an inpatient psychiatric service. Psychiatric Services 47: , Haller E, McNiel DE, Binder RL: Impact of a smoking ban on a locked psychiatric unit. Journal of Clinical Psychiatry 57: , Greeman M, McClellan TA: Negative effects of a smoking ban on an inpatient psychiatry service. Hospital and Community Psychiatry 42: , 1991 Psychiatric Services seeks expert reviewers in the following areas: Cost-effectivness of drug and alcohol treatment Work with the police Psychiatry in other countries Experiences of patients and former patients Telemedicine and telecommunications Outcome and clinical measurement scales Depot medications Length of stay Quality of life Reviewers should be familiar with the literature in their areas of expertise, should have published in peerreviewed journals, and should be familiar with the content and focus of Psychiatric Services. Prospective reviewers should send a curriculum vitae, specifying areas of interest, to John A. Talbott, M.D., Editor, Psychiatric Services, APA, 1400 K Street, N.W., Washington, D.C ( , psjournal@psych.org).
Cigarette Smoking and Its Comorbidity
Cigarette Smoking and Its Comorbidity Alexander H. Glassman Comorbidity is the existence of two conditions in the same individual at a greater frequency than would be expected by chance alone. The existence
More informationNeurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP
Neurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP Disclosures This speaker has no conflicts of interest to disclose Objectives Define drug abuse and addiction Identify the
More informationThe Vermont Legislative Research Shop
The Vermont Legislative Research Shop Smoking Bans and Psychiatric Patients Legislation restricting where cigarettes can be smoked continues to proliferate throughout the country, with some states now
More informationNICOTINE PHARMACOLOGY and PRINCIPLES of ADDICTION. 3 rd of 3 Prep for Session 1
NICOTINE PHARMACOLOGY and PRINCIPLES of ADDICTION 3 rd of 3 Prep for Session 1 CHEMISTRY of NICOTINE Pyridine ring N H N CH 3 Pyrrolidine ring Nicotiana tabacum Natural liquid alkaloid Colorless, volatile
More informationManagement of Tobacco Dependence. Dr. Lokesh Kumar Singh Associate Professor Department of Psychiatry AIIMS, Raipur
Management of Tobacco Dependence Dr. Lokesh Kumar Singh Associate Professor Department of Psychiatry AIIMS, Raipur Difficult to identify any other condition that presents such a mix of lethality, prevalence,
More informationWould smokers with schizophrenia benefit from a more flexible approach to smoking treatment?
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Faculty Publications, Department of Psychology Psychology, Department of June 2002 Would smokers with schizophrenia benefit
More informationSchizophrenia and comorbid cannabis use disorders: Brain structure, function and the effect of antipsychotic medications Machielsen, Marise
UvA-DARE (Digital Academic Repository) Schizophrenia and comorbid cannabis use disorders: Brain structure, function and the effect of antipsychotic medications Machielsen, Marise Link to publication Citation
More informationTobacco Addiction. Addiction Terminology. Jack E. Henningfield, PhD Johns Hopkins School of Medicine Pinney Associates
Tobacco Addiction Jack E. Henningfield, PhD Johns Hopkins School of Medicine Pinney Associates Addiction Terminology Addiction: common term applied to maladaptive drug-seeking behavior Equivalent to American
More informationPSY/NEU338: Animal learning and decision making: Psychological, computational and neural perspectives
Too much dopamine can be bad for you: 1I. Latent inhibition and schizophrenia PSY/NEU338: Animal learning and decision making: Psychological, computational and neural perspectives thanks to Ina Weiner
More informationTreatment Outcomes from the TDC: A Look at Smoking Cessation Among Patients with Co- Occurring Disorders
University of Kentucky From the SelectedWorks of Chizimuzo T.C. Okoli December, 2010 Treatment Outcomes from the TDC: A Look at Smoking Cessation Among Patients with Co- Occurring Disorders Chizimuzo T.C.
More informationWhat are Substance Use Disorders?
What are Substance Use Disorders? Sanchit Maruti, MD Michael Goedde, MD University of Vermont Medical Center 1 Disclosures } Drs. Maruti and Goedde receive compensation as consultants to the American Academy
More informationAntidepressants. Dr Malek Zihlif
Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric
More informationTobacco Treatment during Addictions Treatment or Recovery: A Review of the Literature
Tobacco Treatment during Addictions Treatment or Recovery: A Review of the Literature Judith J. Prochaska, PhD, MPH University of California, San Francisco Research supported by NIDA #P50-DA09253 and #K23-DA018691,
More informationSchizophrenia and tobacco smoking in a Spanish psychiatric hospital $
Schizophrenia Research 60 (2003) 313 317 www.elsevier.com/locate/schres Schizophrenia and tobacco smoking in a Spanish psychiatric hospital $ Adrián LLerena a,b,c, Alfredo de la Rubia b, Eva M. Peñas-Lledó
More informationThe Role of NEUROIMAGING In Diagnostic and Clinical Practice
The Role of NEUROIMAGING In Diagnostic and Clinical Practice ADHD Schizophrenia Autism Addiction Altzheimer s Disease Nora D. Volkow, M.D. Director National Institute on Drug Abuse National Institutes
More informationPsychoactive drugs Drugs which affect mental processes. Legal but restricted (by prescription only)
Psychoactive drugs Drugs which affect mental processes mood, perception, memory, state of consciousness May be illegal: Heroin Cocaine Legal: Alcohol nicotine Legal but restricted (by prescription only)
More informationESSENTIAL PSYCHOPHARMACOLOGY, Neurobiology of Schizophrenia Carl Salzman MD Montreal
ESSENTIAL PSYCHOPHARMACOLOGY, 2011 Neurobiology of Schizophrenia Carl Salzman MD Montreal EVOLVING CONCEPTS OF SCHIZOPHRENIA Psychotic illness with delusions, hallucinations, thought disorder and deterioration;
More informationSchizophrenia. Psychology 372 Physiological Psychology. Overview. Characterized by. Disorganized Thoughts Hallucinations Delusions Bizarre behaviors
Overview Schizophrenia Psychology 372 Physiological Psychology Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Probably consists of more than one disorder Is the most devastating
More informationCHEMISTRY of NICOTINE PHARMACOLOGY NICOTINE ABSORPTION: BUCCAL (ORAL) MUCOSA NICOTINE ABSORPTION. NICOTINE PHARMACOLOGY and PRINCIPLES of ADDICTION
ICOTIE PHARMACOLOGY and PRICIPLES of ADDICTIO ICOTIE ADDICTIO U.S. Surgeon General s Report Cigarettes and other forms of tobacco are addicting. icotine is the drug in tobacco that causes addiction. The
More information590,000 deaths can be attributed to an addictive substance in some way
Mortality and morbidity attributable to use of addictive substances in the United States. The Association of American Physicians from 1999 60 million tobacco smokers in the U.S. 14 million dependent on
More information9/16/2016. I would feel comfortable dispensing/prescribing varenicline to a patient with a mental health disorder. Learning Objectives
The Smoking Gun: for Smoking Cessation in Patients with Mental Health Disorders BRENDON HOGAN, PHARMD PGY2 PSYCHIATRIC PHARMACY RESIDENT CTVHCS, TEMPLE, TX 09/23/2016 I would feel comfortable dispensing/prescribing
More informationMood Disorders and Addictions: A shared biology?
Mood Disorders and Addictions: A shared biology? Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Disclosures No relevant disclosures: No paid
More informationKeywords: tobacco, cigarette smoke, nicotine, dopamine, smoking cessation, acethylcholine, varenicline (champix )
Review Article and Clinical Experience: ENICLINE (CHAMPIX ) : A BREAKTHROUGH FOR SMOKING CESSATION TREATMENT (An α4ß2 Nicotinic Acethylcholine Receptor Partial Agonist) Askandar Tjokroprawiro Diabetes
More informationUnderstanding Addiction and Its Impact on the Brain. SDSMA Webinar Matthew Stanley, DO
Understanding Addiction and Its Impact on the Brain SDSMA Webinar Matthew Stanley, DO Estimated Economic Cost to Society Due to Substance Abuse and Addiction: Illegal drugs: Alcohol: Tobacco: $181 billion/year
More informationUnderstanding the Impact of Cigarette Smoking Using Brain Imaging
Understanding the Impact of Cigarette Smoking Using Brain Imaging Angelica Morales, PhD Postdoctoral Fellow Developmental Brain Imaging Lab Oregon Health & Science University No Financial Disclosures The
More informationMOLECULAR BIOLOGY OF DRUG ADDICTION. Sylvane Desrivières, SGDP Centre
1 MOLECULAR BIOLOGY OF DRUG ADDICTION Sylvane Desrivières, SGDP Centre Reward 2 Humans, as well as other organisms engage in behaviours that are rewarding The pleasurable feelings provide positive reinforcement
More informationSchizophrenia FAHAD ALOSAIMI
Schizophrenia FAHAD ALOSAIMI MBBS, SSC - PSYCH C ONSULTATION LIAISON PSYCHIATRIST K ING SAUD UNIVERSITY Schizophrenia - It is not a single disease but a group of disorders with heterogeneous etiologies.
More informationBreaking the Chains of Nicotine Dependence - A Breakthrough Approach
Breaking the Chains of Nicotine Dependence - A Breakthrough Approach Dr Rob Young Senior Lecturer & Consultant Physician Auckland Hospital, New Zealand Smoking Cessation in 2001 Smoking contributes to
More informationSchizophrenia and Related Psychotic Disorders
and Related Psychotic Disorders Anand K. Pandurangi, MD Professor & Chair, Div. of Inpatient Psychiatry Director, Program VCU Medical Center 1 Kraeplin 1896 Dementia Praecox. Single, Homogenous Disorder
More informationTobacco Dependence Treatment From Neurobiology through Public Policy
Tobacco Dependence Treatment From Neurobiology through Public Policy Mary Ellen Wewers, PhD, MPH, RN Professor Emerita The Ohio State University College of Public Health Disclosures Funding from the National
More informationThe Nervous System Mark Stanford, Ph.D.
The Nervous System Functional Neuroanatomy and How Neurons Communicate Mark Stanford, Ph.D. Santa Clara Valley Health & Hospital System Addiction Medicine and Therapy Services The Nervous System In response
More informationBRAIN MECHANISMS OF REWARD AND ADDICTION
BRAIN MECHANISMS OF REWARD AND ADDICTION TREVOR.W. ROBBINS Department of Experimental Psychology, University of Cambridge Many drugs of abuse, including stimulants such as amphetamine and cocaine, opiates
More informationCigarettes and Other Nicotine Products
Cigarettes and Other Nicotine Products Nicotine is one of the most heavily used addictive drugs in the United States. In 2002, 30 percent of the U.S. population 12 and older 71.5 million people used tobacco
More informationThe study of drugs. Pharmacology
The study of drugs Pharmacology Psychopharmacology The study of psychoactive drugs Psychoactive drugs Drugs that influence psychological processes mood emotion perception cognition behavior Psychoactive
More informationWHAT SHOULD WE KNOW ABOUT MARIJUANA
WHAT SHOULD WE KNOW ABOUT MARIJUANA Marijuana is the most commonly used illicit drug in the U.S. The use of marijuana can produce adverse physical, mental, emotional, and behavioral effects. What is marijuana?
More informationSiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]
SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm
More informationSMOKING CESSATION WORKSHOP. Dr Mark Palayew December
SMOKING CESSATION WORKSHOP Dr Mark Palayew December 5 2016 Conflicts of Interest None Case 1 Mr. T is a 55 year old smoker 2 packs/day He has been smoking continuously since age 16 When he wakes up at
More informationNeurobiology of Addiction. Jon E. Grant, JD, MD, MPH Professor University of Chicago
Neurobiology of Addiction Jon E. Grant, JD, MD, MPH Professor University of Chicago Disclosure Information I have the following financial relationships to disclose: My research is supported by NIDA, AFSP,
More informationsubstance use and mental disorders: one, the other, or both?
substance use and mental disorders: one, the other, or both? Stephen Strobbe, PhD, RN, PMHCNS-BC, CARN-AP Dawn Farm Education Series St. Joe s Education Center, Ypsilanti, MI Tuesday, January 27, 2015
More informationAntipsychotic medication and tobacco use among outpatients with schizophrenia: a cross-sectional study
Wijesundera et al. Annals of General Psychiatry 2014, 13:7 PRIMARY RESEARCH Open Access Antipsychotic medication and tobacco use among outpatients with schizophrenia: a cross-sectional study Hiranya Wijesundera
More informationCouncil on Chemical Abuse Annual Conference November 2, The Science of Addiction: Rewiring the Brain
Council on Chemical Abuse Annual Conference November 2, 2017 The Science of Addiction: Rewiring the Brain David Reyher, MSW, CAADC Behavioral Health Program Director Alvernia University Defining Addiction
More informationThe Neurobiology of Addiction
The Neurobiology of Addiction Jodi Gilman, Ph.D. Center for Addiction Medicine Massachusetts General Hospital Associate Professor, Department of Psychiatry Harvard Medical School What is Addiction? commonly
More informationThe Neurobiology of Drug Addiction
National Institute on Drug Abuse (NIDA) The Neurobiology of Drug Addiction Last Updated January 2007 https://www.drugabuse.gov 1 Table of Contents The Neurobiology of Drug Addiction Section I: Introduction
More informationKey Concepts. Machinery of the Mind. The Growing Cycle. Six Brain Mind Functions. Machinery of the Mind 6/1/2012
Machinery of the Mind How High-risk Choices Redesign the Brain Key Concepts Brain and Mind are reciprocal Brain/Mind Functions intertwine We are hardwired and we have software Your brain changes all the
More informationSupporting smokers with mental health problems
Collaboration for Leadership in Applied Health Research and Care South London (CLAHRC South London) Supporting smokers with mental health problems Ann McNeill, Professor of Tobacco Addiction Dr Debbie
More informationMain Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders
Substance Use Disorders Main Questions Why study addiction? What is addiction? Why do people become addicted? What do alcohol and drugs do? How do we treat substance use disorders? Why study addiction?
More informationPsychopharmacology: A Comprehensive Review
Psychopharmacology: A Comprehensive Review 1) The association between a chemical compound and its biological activity, pioneered by Bovet and colleagues in the 1930s is known as a) Symbiosis b) Structure-activity
More informationNational Institute on Drug Abuse (NIDA) Understanding Drug Abuse and Addiction: What Science Says
National Institute on Drug Abuse (NIDA) Understanding Drug Abuse and Addiction: What Science Says Last Updated February 2016 https://www.drugabuse.gov 1 Table of Contents Understanding Drug Abuse and Addiction:
More informationThe Maudsley Prescribing Guidelines in
The Maudsley Prescribing Guidelines in 11th Edition David Taylor Director of Pharmacy and Pathology South London and Maudsley NHS Foundation Trust; Professor King's College London, London, UK Paton Chief
More informationTony Klein, MPA, CASAC, NCACII
Tony Klein, MPA, CASAC, NCACII Presentation Overview Tobacco Dependence in Individuals with Co-occurring Addictions Challenges and Barriers Organizational Change Strategies Program & System Changes to
More informationCancer Control Office YOUR GUIDE TO QUIT SMOKING
Cancer Control Office YOUR GUIDE TO QUIT SMOKING ARE YOU THINKING ABOUT QUITTING SMOKING? IF YOU ARE, CONGRATULATIONS FOR TAKING THIS IMPORTANT STEP! This brochure will help you: Set your own reasons to
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationPRESCRIBING GUIDELINES
The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors
More informationSetting the Stage: Tobacco s Impact on Smokers, Employers, and Florida
Setting the Stage: Tobacco s Impact on Smokers, Employers, and Florida Thomas H. Brandon, Ph.D. H. Lee Moffitt Cancer Center & Research Institute Florida Tobacco Cessation Summit October 14, 2010 Moffitt
More informationIf you give any person a prescription of something like Valium and have them take it on
As always I am happy to do this presentation, which is my favorite topic in addiction medicine. I am an internist, and I have done healthcare for the homeless in Springfield as well as been the medical
More informationDepression and anxiety as risk factors for failure in smoking cessation attempt among personnel of Tartu University Hospital
Depression and anxiety as risk factors for failure in smoking cessation attempt among personnel of Tartu University Hospital 2010-2012 Ülle Ani 1, Kersti Pärna 2, Inge Ringmets 2, Tiina Mändla 3. 1 Tartu
More informationThe Biological Perspective. Jørg Mørland Senior researcher, Norwegian Institute of Public Health Professor em of Medicine University of Oslo
The Biological Perspective Jørg Mørland Senior researcher, Norwegian Institute of Public Health Professor em of Medicine University of Oslo The Biological Perspective What is it? More than «the» one biological
More informationDifference Between Men and Women in Drug Use Disorders
Archives of Clinical and Medical Case Reports doi: 10.26502/acmcr.96550056 Volume 3, Issue 1 Research Article Difference Between Men and Women in Drug Use Disorders Clairmont Griffith, Bernice La France*
More information11/19/2010. Psychology 472 Pharmacology of Psychoactive Drugs. Indigenous to the Americas 1492 Columbus arrives in West Indies
NICOTINE Nicotine Psychology 472 Pharmacology of Psychoactive Drugs Listen to the audio lecture while viewing these slides Primary active ingredient in tobacco One of the three most widely used psychoactive
More informationPhysical and Physiological Aspects of Drug Use and Abuse
Question 1: What are neurons and neurotransmitters? Answer 1: A neuron is a nerve cell. It is estimated that there are 100 billion neurons in the average human brain (Levinthal, 2008). Neurons receive
More informationAt a Glance. Background Information. Lesson 3 Drugs Change the Way Neurons Communicate
Lesson 3 Drugs Change the Way Neurons Communicate Overview Students build upon their understanding of neurotransmission by learning how different drugs of abuse disrupt communication between neurons. Students
More informationBiopsychosocial Treatment of Nicotine Dependency: Family Participation Versns No Partner Group Treatment
Biopsychosocial Treatment of Nicotine Dependency: Family Participation Versns No Partner Group Treatment Rey Martinez, Ph.D. Ph.D., Florida State University, 1994 Assistant Professor, University of Texas
More informationClinical Guidelines for the Pharmacologic Treatment of Schizophrenia
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationNeuropsychiatry. I. Schizophrenia II. Mood Disorders III. Substance-Related Disorders
Neuropsychiatry I. Schizophrenia II. Mood Disorders III. Substance-Related Disorders I. Schizophrenia Important Initial Contributors Emil Kraepelin Dementia praecox Eugene Bleuler Schizophrenia Positive
More informationSubstance Abuse and Schizophrenia: Editors' Introduction
Substance Abuse and Schizophrenia: Editors' Introduction by Thomas R. Kosten and Douglas M. Ziedords Abstract Most individuals with schizophrenia have problems with abuse of substances ranging from licit
More information^ PRIMER OF DRUG ACTION A comprehensive gyide to the actions, uses, and side effects of psychoactive drugs
^ PRIMER OF DRUG ACTION A comprehensive gyide to the actions, uses, and side effects of psychoactive drugs wm, ROBERT M.JULIEN M.D.. PH.D. Claire D. Advokat, Ph.D. Louisiana State University and Joseph
More informationRisperidone Case 1: Drug-Drug Interactions
Risperidone Case 1: Drug-Drug Interactions 1-14-16 de Leon & Bork (a resident) J Clin Psychiatry 1997;58:450-1 http://www.ncbi.nlm.nih.gov/pubmed/9375597 Jose de Leon, MD Educational Objectives At the
More informationCondensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia
Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia I. Key Points a. Schizophrenia is a chronic illness affecting all aspects of person s life i. Treatment Planning Goals 1.
More informationThe Neurochemistry of Relapse & Recovery Worksheets to accompany the video by CNS Productions, Inc.
The Neurochemistry of Relapse & Recovery Worksheets to accompany the video by CNS Productions, Inc. These worksheets will help you to examine more deeply the reasons for relapse and the challenges inherent
More informationGoal: To identify the extent to which different aspects of brain structure and brain processes might offer explanations for different forms of
Goal: To identify the extent to which different aspects of brain structure and brain processes might offer explanations for different forms of psychopathology The human brain If genetics play a role, it
More informationUnderstanding Addiction: Why Can t Those Affected Just Say No?
Understanding Addiction: Why Can t Those Affected Just Say No? 1 The Stigma of Addiction There continues to be a stigma surrounding addiction even among health care workers. Consider the negative opinions
More informationResearch Paper 21/08/
Research Paper 21/08/18 20.35 D: 1. The nervous system. 2. The nervous system and drugs. 3. How do drugs effect the central nervous system. 4. Stimulants, hallucinogens, depressants and their effects on
More informationMANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER
MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. Peter s Health Partners Grand Rounds October 11, 2017 Disclosures One
More informationWESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS
WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS DOPAMINE HYPOTHESIS Excessive limbic dopamine is hypothesised to cause psychosis Many antipsychotics inhibit dopamine 2 receptors in mesolimbic and
More informationStages of Change in Smokers With Schizophrenia or Schizoaffective Disorder and in the General Population
Stages of Change in Smokers With Schizophrenia or Schizoaffective Disorder and in the General Population by Manuela Etter, Sylvia Mohr, Claire Qarin, and Jeari'Frangois Etter Abstract This study compared
More informationSmoking cessation and reduction in people with chronic mental illness
Link to this article online for CPD/CME credits Smoking cessation and reduction in people with chronic mental illness Center for Alcohol and Addiction Studies, Brown University, Providence, RI 02912, USA
More informationGUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS
City and County of San Francisco Mayor Gavin Newsom Department of Public Health Community Behavioral Health Services 1380 Howard Street 5 th Floor San Francisco, CA 94103 GUIDELINES FOR THE USE OF PSYCHOACTIVE
More informationSmoking by people with mental illness and benefits of smoke-free mental health services
Smoking by people with mental illness and benefits of smoke-free mental health services Jonathan Campion, Ken Checinski, Jo Nurse and Ann McNeill Adv. Psychiatr. Treat. 2008 14: 217-228 Access the most
More informationClasses of Neurotransmitters. Neurotransmitters
1 Drugs Outline 2 Neurotransmitters Agonists and Antagonists Cocaine & other dopamine agonists Alcohol & its effects / Marijuana & its effects Synthetic & Designer Drugs: Ecstasy 1 Classes of Neurotransmitters
More informationREACH, ENGAGE, HELP:
REACH, ENGAGE, HELP: Smokers with Mental Illness Judith J. Prochaska, PhD, MPH UCSF Department of Psychiatry The Death of a 56-Year-Old Man With Serious Mental Illness A 56-year-old, gay-identified Caucasian
More informationProject TEACH. Smoking Cessation For People With Schizophrenia. Maher Karam Hage, MD Professor, Depts. Of Behavioral Science and Psychiatry
Project TEACH Smoking Cessation For People With Schizophrenia Maher Karam Hage, MD Professor, Depts. Of Behavioral Science and Psychiatry Outline 1) What is behind the high comorbidity between Schizophrenia
More informationEARLY ONSET SCHIZOPHRENIA
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences EARLY ONSET SCHIZOPHRENIA JON MCCLELLAN CHILD STUDY AND TREATMENT CENTER GENERAL DISCLOSURES The University of Washington
More informationTianeptine Dependence: A Case Report
CASE REPORT Tianeptine Dependence: A Case Report Syed Nabil, Ng Chong Guan, Rusdi Abd Rashid Department of Psychological Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia Abstract
More informationJennifer W. Tidey Publication List 09/15/11
PUBLICATIONS LIST ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS 1. Miczek KA, Haney M, Tidey J, Vatne T, Weerts E, DeBold JF (1989). Temporal and sequential patterns of agonistic behavior: Effects of
More informationPsychopathology: Biological Basis of Behavioral Disorders
1 6 Psychopathology: Biological Basis of Behavioral Disorders 16 Psychopathology: Biological Basis of Behavioral Disorders The Toll of Psychiatric Disorders Is Huge Schizophrenia is the major neurobiological
More informationRole of Clozapine in Treatment-Resistant Schizophrenia
Disease Management and Treatment Strategies Elkis H, Meltzer HY (eds): Therapy-Resistant Schizophrenia. Adv Biol Psychiatry. Basel, Karger, 2010, vol 26, pp 114 128 Role of Clozapine in Treatment-Resistant
More informationThe Impact of Mental Illness on Sexual Dysfunction
Balon R (ed): Sexual Dysfunction. The Brain-Body Connection. Adv Psychosom Med. Basel, Karger, 2008, vol 29, pp 89 106 The Impact of Mental Illness on Sexual Dysfunction Zvi Zemishlany Abraham Weizman
More informationEffective Treatments for Tobacco Dependence
Effective Treatments for Tobacco Dependence Abigail Halperin MD, MPH Director, University of Washington Tobacco Studies Program Ken Wassum Associate Director of Clinical Development and Support Quit for
More information6B / Boswell, Grant and Slutske Day 2 August 14, 2008
Pharmacological Treatment of Pathological Gambling Jon E. Grant, JD, MD, MPH Associate Professor University of Minnesota School of Medicine Minneapolis, MN Disclosure Information I have the following financial
More informationTeen Mental Health and Substance Abuse. Cheryl Houtekamer AHS - AADAC Youth Services Calgary
Teen Mental Health and Substance Abuse Cheryl Houtekamer AHS - AADAC Youth Services Calgary Agenda Me? Talk about mental health?? Adolescent development Brain development Adolescent drug use Mental health
More informationThe Human Animal Drugs of Plant Origin
The Human Animal Drugs of Plant Origin Plant Secondary Compounds The Spice of Life Cultural Use of Spices Spice Use by Region 1 Silurian Land Plants History of Insect Damage 416-447 MYA Colonization of
More informationDrugs 101: Behavioral Pharmacology
Drugs 101: Behavioral Pharmacology Eb Blakely, Ph.D., BCBA-D Quest, Inc./Florida Institute of Technology Drug Facts Drug effects are dose-dependent Drugs effects are time-dependent Drugs are toxic at high
More information- Neurotransmitters Of The Brain -
- Neurotransmitters Of The Brain - INTRODUCTION Synapsis: a specialized connection between two neurons that permits the transmission of signals in a one-way fashion (presynaptic postsynaptic). Types of
More informationDr. Fred Rose. Schizophrenia. Nature of Schizophrenia and Psychosis: An Overview. Prevalence of Schizophrenia 10/20/10. Schizophrenia vs.
Schizophrenia Dr. Fred Rose Nature of Schizophrenia and Psychosis: An Overview Schizophrenia vs. Psychosis Psychosis Cluster of disorders; hallucinations and/or loss of contact with reality Schizophrenia
More informationUpdate on Medications for Tobacco Cessation
Update on Medications for Tobacco Cessation Marc Fishman MD Johns Hopkins University Dept of Psychiatry Maryland Treatment Centers Baltimore MD MDQuit Best Practices Conference Jan 2013 Nicotine Addiction
More informationTobacco treatment for people with serious mental illness (SMI)
Tobacco treatment for people with serious mental illness (SMI) An opportunity to close the mortality gap Massachusetts Mental Health Center 1 National Resource Center for Academic Detailing A compelling
More informationTreatment of Children and Adolescents with Schizophrenia
Treatment of Children and Adolescents with Schizophrenia The evidence base pertaining to the pharmacotherapy of schizophrenia in children and adolescents (C&A) is tiny compared to what is available for
More informationSmoking vs Smokeless. Tobacco is a plant that contains nicotine. Cigars and pipes contain more tar and other chemicals.
Tobacco Smoking vs Smokeless Tobacco is a plant that contains nicotine. Cigars and pipes contain more tar and other chemicals. Smoking Tobacco is tobacco that is smoked or inhaled. Smokeless tobacco is
More informationBehavior Therapy. Therapy that applies learning principles to the elimination of unwanted behaviors.
Behavior Therapy Therapy that applies learning principles to the elimination of unwanted behaviors. To treat phobias or sexual disorders, behavior therapists do not delve deeply below the surface looking
More informationTobacco Free State Psychiatric Hospitals and Continuity of Care in the Community
Tobacco Free State Psychiatric Hospitals and Continuity of Care in the Community My Background DMH Medical Director Consultant to MoHealthNet (Missouri Medicaid ) President NASMHPD Medical Director s Council
More information